People In Brief
This article was originally published in The Gray Sheet
Executive Summary
OrbusNeich adds sales experience: Genous Bio-engineered R-Stent maker appoints Massimo Chiesa and Per Arne Winberg to its expanding sales and marketing team July 30. Chiesa, who has worked for EuroCor International, Volcano Therapeutics, Jomed and SCIMed (now part of Boston Scientific), is now OrbusNeich's director for Western Europe, the Middle East and Latin America. Winberg brings sales experience from Abbott Vascular, Jomed and Johnson & Johnson/Cordis and becomes director for Northern and Eastern Europe. Antibody-coated Genous was CE-marked in 2005. OrbusNeich touts the device as a safer alternative to drug-eluting stents and is seeking entry into the U.S. market (1"The Gray Sheet" May 28, 2007, p. 5)...
You may also be interested in...
OrbusNeich Says “Bio-Engineered” Stent May Be Solution To Thrombosis Risk
OrbusNeich hopes to lead a new wave of stent technology with its Genous Bio-engineered R-Stent, which the firm says is safer than existing drug-eluting stents because it has a natural antibody coating instead of a drug-eluting polymer
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.